Curemeta
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
27 Drydock Ave Ste 28, Boston, Massachus...Phone Number
(857) 263-8343Website
www.curemeta.comRevenue
<$5 MillionIndustry
About Curemeta
CureMeta is a Boston-based biotech company focused on developing innovative antibodies and Antibody-Drug-Conjugates (ADCs) to target and treat metastatic cancers, particularly pancreatic and gastric cancers. Their lead therapeutic, CM-09, is a humanized antibody that specifically binds to the cancer stem cell marker TRA-1-60, which is present in aggressive tumors but absent in healthy tissues. The company aims to transition from preclinical to clinical trials, with plans to initiate a Phase 1 study to evaluate the safety and efficacy of their therapies. CureMeta's mission is to provide effective treatment options for patients suffering from metastatic cancers, addressing a significant unmet medical need.Explore more
Curemeta Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Curemeta
Compare insights from companies similar to Curemeta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Curemeta Tech Stack
A closer look at the technologies used by Curemeta
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curemeta
Sign Up For FreeTo access detailed company insights
CureMeta is a Boston-based biotech company focused on developing innovative antibodies and Antibody-Drug-Conjugates (ADCs) to target and treat metastatic cancers, particularly pancreatic and gastric cancers. Their lead therapeutic, CM-09, is a humanized antibody that specifically binds to the cancer stem cell marker TRA-1-60, which is present in ag... Read More
